Pharming Group reports financial results for the first nine months of 2021
Financial updatesPharming Group presents its preliminary (unaudited) financial report for the first nine months ended September 30, 2021.
Pharming Group presents its preliminary (unaudited) financial report for the first nine months ended September 30, 2021.
Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/NASDAQ: PHAR) announces the topline results from two randomized, open label, controlled, pilot clinical trials of patients hospitalized with COVID-19 treated with RUCONEST® (recombinant human C1 inhibitor) for the prevention of severe SARS-CoV-2 infection. The primary endpoint in both studies was disease severity on the 7-point WHO ordinal scale on Day 7.
Recovery continued into Q2 2021 as patient enrollment and product demand increases
Pharming’s CEO Sijmen de Vries and CFO Jeroen Wakkerman look back at the first half of 2021 and the recently published full year financial results.
We are deeply saddened to announce the passing of our former Chairman Drs. Jakob (Jaap) Blaak.
Wilt u overschakelen naar een andere taal? Klik hier voor de Nederlandse website.